Patents by Inventor Philip Barr

Philip Barr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080085854
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Application
    Filed: July 20, 2007
    Publication date: April 10, 2008
    Inventors: Philip Barr, Helen Gibson, Philip Pemberton
  • Publication number: 20070117748
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Application
    Filed: July 14, 2006
    Publication date: May 24, 2007
    Applicant: TANOX, INC.
    Inventors: Michael Kiefer, Philip Barr
  • Publication number: 20070105768
    Abstract: A dry powder composition comprises recombinant human alpha 1-antitrypsin (rAAAT).
    Type: Application
    Filed: November 10, 2004
    Publication date: May 10, 2007
    Inventors: Rajiv Nayar, Mark Manning, Philip Barr, Philip Pemberton, Ian Bathurst, Helen Gibson
  • Publication number: 20070099215
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Application
    Filed: October 9, 2006
    Publication date: May 3, 2007
    Applicant: TANOX INC.
    Inventors: Michael Kiefer, Paul Fitzpatrick, Helen Gibson, Philip Barr
  • Publication number: 20060148052
    Abstract: Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.
    Type: Application
    Filed: October 27, 2005
    Publication date: July 6, 2006
    Applicant: Kosan Biosciences, Inc.
    Inventors: Philip Barr, Daniel Santi, Gary Ashley, Rainer Ziermann
  • Publication number: 20050201951
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
    Type: Application
    Filed: March 9, 2005
    Publication date: September 15, 2005
    Inventors: Philip Barr, Philip Pemberton, Helen Gibson
  • Publication number: 20050164284
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Application
    Filed: March 16, 2005
    Publication date: July 28, 2005
    Applicant: Tanox, Inc.
    Inventors: Michael Kiefer, Philip Barr
  • Publication number: 20050107306
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of respiratory diseases associated with matrix metalloproteases. More specifically, the present invention relates to the treatment and prevention of respiratory diseases associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors. Exemplary respiratory diseases associated with matrix metalloproteases that may be treated by the methods of the invention include chronic obstructive pulmonary disease, emphysema, asthma, cystic fibrosis, and chronic bronchitis. An exemplary synthetic matrix metalloprotease useful in the methods of the invention is ilomastat.
    Type: Application
    Filed: May 17, 2004
    Publication date: May 19, 2005
    Inventors: Philip Barr, Philip Pemberton
  • Publication number: 20050084972
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Application
    Filed: August 9, 2004
    Publication date: April 21, 2005
    Inventors: Philip Barr, Helen Gibson
  • Patent number: 4997647
    Abstract: Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
    Type: Grant
    Filed: October 25, 1988
    Date of Patent: March 5, 1991
    Assignees: New York University, Chiron Corporation
    Inventors: Victor Nussenzweig, Philip Barr